Oruka Therapeutics Balance Sheet
NASDAQ: ORKAHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Oruka Therapeutics financial position
At the end of fiscal 2025, Oruka Therapeutics reported total assets of $488.6 million, up 1190.6% from a year earlier against total liabilities of $16.7 million. Shareholders' equity stood at $471.9 million, or 96.6% of assets. The company held $46.9 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 22.37, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Oruka Therapeutics balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 | FY 20152015-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 46.94M | 37.43M | 42.45M | 53.36M | 49.07M | 8.36M | 6.61M | 8.70M | 7.40M | 38.80M |
| Short-Term Investments | 290.11M | — | — | — | — | — | — | 3.05M | 13.76M | — |
| Total Current Assets | 343.86M | 37.59M | 42.70M | 54.42M | 49.97M | 8.48M | 6.78M | 12.30M | 21.45M | 38.92M |
| Property, Plant & Equipment | 288.00K | 10.00K | 25.00K | 48.00K | 21.00K | 10.00K | 24.00K | 42.00K | 66.00K | 28.00K |
| Long-Term Investments | 142.54M | — | — | — | — | — | — | — | 2.35M | — |
| Total Assets | 488.62M | 37.86M | 43.09M | 54.92M | 50.43M | 8.54M | 6.83M | 12.37M | 24.63M | 39.57M |
| Accounts Payable | 4.16M | 362.00K | 334.00K | 1.12M | 1.77M | 418.00K | 230.00K | 622.00K | 1.21M | 364.00K |
| Total Current Liabilities | 15.37M | 637.00K | 1.13M | 3.50M | 3.50M | 926.00K | 793.00K | 2.07M | 2.40M | 1.50M |
| Total Liabilities | 16.69M | 841.00K | 1.41M | 3.88M | 3.91M | 926.00K | 793.00K | 2.09M | 2.44M | 1.50M |
| Shareholders' Equity | 471.93M | 37.02M | 41.67M | 51.04M | 46.52M | 7.61M | 6.03M | 10.28M | 22.19M | 38.07M |
| Retained Earnings | -189.16M | -188.74M | -183.40M | -173.48M | -154.15M | -144.42M | -138.93M | -131.00M | -112.51M | -96.07M |
| Net Cash (Debt) | 337.04M | 37.43M | 42.45M | 53.36M | 49.07M | 8.36M | 6.61M | 11.75M | 21.16M | 38.80M |
| Shares Outstanding | 48.72M | 14.50M | 14.41M | 14.41M | 9.55M | 1.59M | 773.56K | 11.78M | 9.08M | 9.05M |
This table shows 10 annual periods of Oruka Therapeutics's balance sheet, from FY 2025 back to FY 2015, across 13 line items including cash & equivalents, short-term investments, total current assets. Values in USD; B = billions, M = millions. Fiscal periods follow ORKA's reporting calendar. What is a balance sheet?